Connect Biopharma Holdings (CNTB) Operating Expenses (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Operating Expenses for 3 consecutive years, with $19.8 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Expenses rose 72.76% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.5 million (up 40.53% YoY) and the FY2025 annual result came in at $58.1 million, up 19.91% from the prior year.
• Operating Expenses grew to $19.8 million in Q1 2026 per CNTB's latest filing, from $15.5 million in the prior quarter.
• Over the last five years, Operating Expenses for CNTB reached as high as $19.8 million in Q1 2026 and fell as low as $10.3 million in Q4 2024.
• A 3-year average of $14.0 million and a median of $13.5 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2025 — Operating Expenses retreated 9.39% — and 2026, when it surged 72.76%.
• Year by year, Operating Expenses stood at $10.3 million in 2024, then surged by 50.49% to $15.5 million in 2025, then climbed by 27.37% to $19.8 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $19.8 million, $15.5 million, and $17.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.